Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
Holding IVVD?
Track your performance easily
IVVD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.40 - $5.20
Previous Close$0.44
Volume2.34M
Average Volume (3M)628.62K
Market Cap
$51.40M
Enterprise Value-$53.87M
Total Cash (Recent Filing)$106.87M
Total Debt (Recent Filing)$1.60M
Price to Earnings (P/E)―
Beta2.19
Next Earnings
Mar 27, 2025EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding119,616,035
10 Day Avg. Volume815,921
30 Day Avg. Volume628,624
Standard Deviation0.41
R-Squared0.00410
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.63
Price to Sales (P/S)11.35
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.66
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$7.52Price Target Upside1594.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Invivyd News
PremiumCompany Announcements
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase 3 trial data showed that PEMGARDA provided significant protection against symptomatic COVID-19, demonstrating a substantial risk reduction compared to a placebo.
Market DemandThere is belief in a market for an active monoclonal antibody against COVID given the unmet need among moderate-to-severe immunocompromised individuals.
Regulatory UpdatesThe FDA updated the PEMGARDA Fact Sheet to include accurate data on its antiviral activity, which could restore confidence in the product.
Bears Say
Financial PerformanceThe withdrawal of 2024 financial guidance is disappointing due to lower-than-expected revenues and cash estimates.
Product SalesPemgarda net product revenue of $9.3 million came in well short of consensus at $32 million, highlighting significant sales underperformance.
Regulatory ImpactPemgarda sales were negatively impacted by confusion caused by an incorrect FDA Fact Sheet that created doubt among healthcare providers.
---
Ownership Overview
32.07% Insiders
8.31% Mutual Funds
39.51% Other Institutional Investors
13.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.40 and its highest was $5.20 in the past 12 months.
What is Invivyd’s market cap?
Currently, no data Available
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Nov 14, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.172.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -$0.3.
How many shares outstanding does Invivyd have?
Invivyd has 119,616,035 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -11.236%.
Which hedge fund is a major shareholder of Invivyd?
Among the largest hedge funds holding Invivyd’s share is Maverick Capital ltd. It holds Invivyd’s shares valued at 12M.
---
Invivyd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.52 (1594.08% Upside)
$7.52 (1594.08% Upside)
Blogger Sentiment
Bullish
IVVD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 53.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $536.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.98%
12-Months-Change
Fundamentals
Return on Equity
-136.59%
Trailing 12-Months
Asset Growth
-41.10%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
---
IVVD Company Deck
---
IVVD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed sentiment with significant achievements in clinical results and product growth being overshadowed by commercial headwinds and the withdrawal of revenue guidance.Read More>---
IVVD Stock 12 Month Forecast
Average Price Target
$7.52
▲(1594.08% Upside)
Technical Analysis
Best Analysts Covering IVVD
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-42.61%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -42.61% per trade.
---